MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the closing of its previously announced public offering of an aggregate of 4,000,000 of the Company’s ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company’s ordinary shares, at a combined public offe ...

Core Viewpoint - Lifeward Ltd. has announced a public offering of 4,000,000 ordinary shares and accompanying warrants at a price of $0.65 per share, aiming to raise approximately $2.6 million for commercial efforts and working capital [1][3]. Group 1: Offering Details - The public offering includes 4,000,000 ordinary shares and warrants to purchase an additional 4,000,000 shares at the same price of $0.65 [1]. - The ordinary warrants will be exercisable immediately and will expire five years from the issuance date [1]. - The expected gross proceeds from the offering are approximately $2.6 million before deducting fees and expenses [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for continuing commercial efforts, working capital, and general corporate purposes [3]. Group 3: Regulatory Information - The offering is being conducted under a registration statement on Form S-1, which was declared effective by the SEC on June 25, 2025 [4]. - A preliminary prospectus has been filed with the SEC and is available on their website [4]. Group 4: Company Overview - Lifeward Ltd. specializes in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [6]. - The company’s product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System [6]. - Founded in 2001, Lifeward operates in the United States, Israel, and Germany [6].

Decision at the highest levels of appeal in the Medicare process establishes medical necessity of the ReWalk Exoskeleton for enabling paralyzed individuals to stand and walk in everyday environments.MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the recent ruling by an Adminis ...

Lifeward (LFWD) Conference Summary Company Overview - **Company**: Lifeward Limited - **Industry**: Medical Devices, specifically focused on rehabilitation technologies such as exoskeletons and functional electrical stimulation devices Key Points and Arguments Future Growth and Positioning - Lifeward has developed leading innovative technologies aimed at fundamentally changing lives, with a focus on commercialization [4][6] - The company has achieved significant milestones, including Medicare coverage for personal exoskeletons, which positions them for future growth [9][31] Product Portfolio - Lifeward's product lineup includes: - **ReWalk**: A personal exoskeleton for restoring functional walking [12][43] - **AlterG**: An antigravity system for rehabilitation [35][38] - **MyoCycle FES**: A functional electrical stimulation bike for therapy [40][41] - **ReStore Exosuit**: A soft exoskeleton primarily for stroke patients [43][44] Market Access and Reimbursement - The company has made strides in reimbursement coverage, with significant contracts established in the U.S. and Germany [29][31] - Lifeward is focusing on expanding into the commercial market and enhancing relationships with workers' compensation [30][32] Market Size and Potential - The total addressable market for ReWalk in the U.S. is approximately 15,000 eligible candidates, with an additional 2,000 in Germany, indicating a substantial growth opportunity [34] - The company is targeting a broader market with its various products, aiming for profitability through market penetration [34][71] Financial Performance and Path to Profitability - Lifeward expects to achieve revenue between $28 million to $30 million for the current year, with a goal of reaching breakeven at $40 million to $45 million in revenue by 2026 [47][71] - The company has improved gross margins through efficient operations and product mix [48][65] Product Development and Innovation - Lifeward has launched new versions of its products, enhancing user experience with features like smoother movement and better control [18][19][21] - Continuous feedback from users has driven product improvements, emphasizing the importance of user experience in rehabilitation technologies [27][28] Industry Dynamics - The medical device industry is fragmented, presenting opportunities for future consolidation as Lifeward continues to grow and integrate its product lines [46][47] - The company is strategically positioned to leverage its clinic presence to drive referrals and enhance product adoption [67][68] Additional Important Information - Lifeward's products are manufactured in various locations, with ReWalk produced in Israel and other products made in the U.S. [72] - The company has navigated tariff concerns effectively, with protocols in place to mitigate potential impacts [72] This summary encapsulates the key insights from the Lifeward conference, highlighting the company's strategic direction, product offerings, market potential, and financial outlook.

Industry veteran brings 30 years of commercial leadership experienceMARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company’s new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward’s outgoing CEO, will ...

Core Insights - Lifeward Ltd. reported a revenue of $5.0 million for Q1 2025, a decrease from $5.3 million in Q1 2024, primarily due to lower sales of ReWalk Exoskeletons and MyoCycles [4][9] - The company experienced a significant increase in gross margin to 42.2% in Q1 2025, up from 26.4% in Q1 2024, attributed to a favorable mix of payors and higher sales volume of AlterG systems [5][29] - Lifeward's operating loss improved to $4.9 million in Q1 2025 from $6.5 million in Q1 2024, indicating better cost management and operational efficiency [8][9] Financial Performance - Revenue from AlterG products and services increased by 17% to $3.3 million in Q1 2025, driven by higher international demand [4] - Operating expenses decreased to $7.0 million in Q1 2025 from $7.9 million in Q1 2024, reflecting cost savings from the closure of certain facilities [6][7] - The net loss narrowed to $4.8 million, or $0.46 per share, compared to a net loss of $6.3 million, or $0.73 per share, in the prior year [9][23] Market Developments - Lifeward launched the ReWalk 7 exoskeleton in the U.S. market following FDA clearance, marking a significant product advancement [6] - The company secured its first approval for a ReWalk 7 claim from a major U.S. commercial health insurance provider, expanding its market reach beyond Medicare [6] - Lifeward established a partnership with CorLife for exclusive distribution of the ReWalk Personal Exoskeleton to individuals with workers' compensation claims, aiming for greater market penetration [6] Liquidity and Guidance - As of March 31, 2025, Lifeward had $5.7 million in unrestricted cash and cash equivalents, with no debt, indicating a stable liquidity position [10] - The company expects full-year revenue for 2025 to be in the range of $28 million to $30 million, reflecting optimistic growth prospects [11]

Core Viewpoint - Lifeward Ltd. is set to release its first quarter 2025 financial results on May 15, 2025, before market opening, indicating a focus on transparency and communication with investors [1]. Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1]. - The company designs, develops, and commercializes solutions that provide functional and health benefits across various care settings, including clinical environments and home care [3]. - Lifeward's product portfolio includes notable innovations such as the ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES System, and ReStore Exo-Suit, showcasing its commitment to driving innovation in rehabilitation [3]. Financial Communication - The CEO Larry Jasinski and CFO Mike Lawless will host a conference call and live webcast on May 15, 2025, at 8:30 a.m. EDT to discuss the financial results, emphasizing the company's commitment to engaging with analysts and investors [2]. - Access to the conference call will be available through multiple channels, including toll-free numbers for various regions and a live webcast on the company's website [2].